# A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

> **NCT03165422** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 68 (actual)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT03165422
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2018-12-29
- **Final completion:** 2018-12-29
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165422, "A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03165422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*